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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of death in the
United States (U.S), with rates in Kentucky among the highest in the nation. Quality care in the
primary care setting is key to optimizing the health outcomes of those with COPD.
Purpose: The objective of this study was to establish a baseline of COPD patient care in a
primary care clinic. The specific aims of this study were to: 1) describe the demographic and
health-related characteristics of patients with COPD who have a primary care provider (PCP) at
one Norton Healthcare primary care clinic; 2) explore relationships among key variables; and, 3)
evaluate provider adherence to COPD evidence-based practice (EBP) guidelines.
Methods: The study was conducted as a retrospective chart review, including a sample of
patients (N=215) from the clinic between January 1, 2015 and December 31, 2015.
Results: Tobacco smokers have more exacerbations than former and never smokers; those with a
heart failure (HF) comorbidity were more likely to have had a COPD exacerbation, and were
more likely to be hospitalized with a COPD exacerbation; and, those with a diabetes mellitus
(DM) comorbidity were also more likely to be hospitalized with a COPD exacerbation. The
studied clinic did not meet national benchmarks for bronchodilator therapy, timely PCP followup after hospital discharge, or readmission rates.
Conclusion: The results of this study indicate a need for a practice improvement intervention
involving program implementation to reduce hospitalizations. Specific aims of the program
include: 1) spirometry evaluation in the clinic for objective diagnosis and staging of COPD; 2)
optimizing the electronic medical record (EMR) with the addition of COPD templates; and, 3)
creating a process for timely follow-up after hospital discharge, particularly for patients with HF
or DM.
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Baseline of COPD Management in a Norton Healthcare Primary Care Clinic
Background
Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of death in the United
States. Death rates for stroke and heart disease have significantly declined over the last 10-20
years, while death rates for COPD have steadily increased (Kochanek, Murphy, Xu, & TejadaVera, 2016). United States healthcare costs attributed to COPD in 2010 were $32.1 billion, and
are projected to be $49 billion by year 2020 (Centers for Disease Control and Prevention [CDC],
2014). The National 2010 healthcare costs associated with COPD were paid mostly by state
federal and state funds (51% by Medicare, 25% by Medicaid), with only 18% by private
insurance (CDC, 2014).
Kentucky is among the states with the highest rates of COPD in the nation, with a near
15% rate in those over age 55 (National Institutes of Health, National Heart, Lung, and Blood
Institute [NHLBI], 2012). The rate of readmission within 30 days for COPD is between 16.3% 28% nationally, with Louisville, Kentucky among those with the highest rates from July 2012 –
June 2013 (Centers for Medicare and Medicaid Services [CMS], 2014).
The Triple Aim Initiative of the Institute for Healthcare Improvement ([IHI], 2016)
includes: 1) the improvement of patient care experience; 2) the improvement of population
health outcomes; and, 3) the reduction of healthcare costs. Targeting improvements in the
medical management of COPD can specifically address all three components of the Triple Aim.
A CMS prevention quality indicator (PQI) points to COPD as a disease (along with asthma) that
can be controlled in an outpatient setting, with the claim that high-quality outpatient care reduces
preventable hospital admissions (CMS, 2016). Hospital admission and readmission rates above
national average would suggest a need for improvement in the outpatient management of COPD.
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Practice Guideline Overview
The leading evidence-based COPD clinical practice guideline is the Global Strategy for
the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Global
Initiative for Chronic Obstructive Lung Disease [GOLD], 2015). Goals for treatment in the
management of stable COPD are to reduce symptoms of COPD and reduce the risk of COPD
exacerbation. The presence of certain disease comorbidities change the risk for COPD events
and have a negative impact on disease prognosis and health outcomes, and are therefore given
consideration in the guidelines (GOLD, 2015).
To make a clinical diagnosis of COPD, the guideline clearly states that spirometry is
required, with a resulting post-bronchodilator forced expiratory volume/forced vital capacity
ratio (FEV1/FVC) less than 70% (<0.70). Treatment recommendations are based on severity of
COPD and impact on patient health status, including risk for exacerbations, hospitalization, or
death. The GOLD combined assessment of COPD categorizes people A through D, according to
subjective and objective assessment results, with groups C and D being high risk for
exacerbation and poor health outcomes. Subjective assessment is measured by scores on an
evidence-based survey, objective assessment is based on spirometry findings, and the final
category regards exacerbations per year (< 1 or > 2), which is the only measure of assessment
applicable to this study.
Pharmacologic treatment recommendations are based on the group in which the patient is
categorized. Table 1 lists the first line long-term pharmacologic recommendations, which are
based on severity of disease or rather, whether patient fits into patient group A, B, C, or D. The
types of medications listed in the table include: short-acting anticholinergic (SAA), short-acting
beta2-agonist (SABA), long-acting anticholinergic (LAA), long-acting beta2-agonist (LABA),
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and inhaled corticosteroid (ICS). In the event of an exacerbation, the goal is to minimize
exacerbation impact and prevent subsequent exacerbations. Treatment preference for
exacerbation includes SABAs with or without SAAs, with systemic corticosteroids and
antibiotics often being indicated, depending on symptom severity (GOLD, 2015). There is
substantial evidence to support primary care management of COPD per GOLD (2015)
recommendations, however, there is little research specific to patient outcomes related to
implementation of GOLD recommendations in the primary care setting.
Purpose
The purpose of this study was to establish a baseline of COPD patient care in a primary
care clinic to inform quality improvement initiatives to reduce preventable hospitalizations for
COPD. The specific aims were to:
1. Describe demographic and health-related characteristics of all specified patients of the
Norton primary care clinic with COPD during January 1, 2015 through December 31,
2015.
2. Explore relationships among key variables (eg. comorbidities and COPD
exacerbations).
3. Evaluate provider adherence to GOLD (2015) guideline recommendations.
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Methods
Setting and Sample
The application to perform this retrospective chart review was approved by the
Institutional Review Board (IRB) of the University of Kentucky and the Norton Healthcare
Office of Research Administration (NHORA). The setting for this study was a primary care
clinic of Norton Healthcare, located in Louisville, Kentucky. Subjects of the study included the
entire population of patients (N=215) who met study inclusion criteria between January 1, 2015
and December 31, 2015.
Inclusion criteria consisted of the following: age 40 or older; had an outpatient visit
(addressing COPD) to the clinic between January 1, 2015 and December 31, 2015; and, had a
PCP at the clinic. Diagnostic codes included were: International Classification of Disease Ninth
Edition (ICD-9), 490, 491, 492, 494, 496; ICD Tenth Edition (ICD-10) J44.0, J44.1, J44.9; and,
Medicare Severity Diagnostic Related Groups (MS-DRGs) 190, 191, 192, 202, or 203.
Exclusion criteria included: under 40 years of age; without an outpatient visit addressing COPD
diagnosis or symptom management between January 1, 2015 and December 31, 2015; became
patient of the clinic after January 1, 2015; employee of the Fincastle clinic; and/or, personal
acquaintance or associate of the principal investigator (PI).
Data Collection
Norton Health Information Management (HIM) personnel provided a report based on
study inclusion criteria. An electronic crosswalk table data collection tool was assembled to
simplify the data collection process. The variables for data collection are within the results
section and tables within the Appendix of this manuscript. All data was collected through Epic
(Epic Hyperspace, Released 2015), the electronic medical record (EMR) platform used by
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Norton Healthcare. The data was entered into the data collection tool, with all data analyzed
through the IBM SPSS program (SPSS Version 22, Released 2013).
Statistical Analysis
Descriptive statistical analysis was used to summarize the data within IBM SPSS (SPSS
Version 22, Released 2013). Non-parametric statistical analyses were used to evaluate
relationships and establish correlations between variables. Bivariate analyses were used to
evaluate relationships between two variables. Chi-square test for independence was used to
discover relationships between two nominal or categorical variables. The Mann-Whitney U
tested for group differences between nominal and ordinal variables, including mean rank and
median comparisons. Spearman’s Rank Order Correlation (Spearman’s rho) tested for
correlation between two ordinal variables. Statistical significance was determined by a p value
less than or equal to 0.05 (p=<0.05). If significant, the effect size was defined as small (r=0.10
to 0.29), medium (r=0.30 to 0.49), or large (r=0.50 to 1.0) based on the widely accepted Cohen
(1988) guidelines outlined in the SPSS text (Pallant, 2013).
Results
The study sample included 215 patients aged 41 to 94 years, with a median age of 65.
Tables 2, 3, 4, and 5 demonstrate the detailed results from the study. In summary, most patients
were white (66%) or black (34%), and the gender studied was mostly female (67%) versus male
(33%). Most of the patients in this sample were current smokers (52%) or former smokers
(43%). The four categories for insurance type were Medicare (65%), Medicaid (24%),
commercial or private (10%), and other or no insurance (1%). Figure 1 illustrates that the payer
distribution for this study is consistent with the 2010 national data reported by the CDC (2014).
Table 6 demonstrates the findings that insurance type was not correlated with COPD
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hospitalizations or readmissions. Commercial or private insurance was not presented in this
table due to an inadequate sample size for testing.
Exacerbations
There were 45 (21%) people in the study (N=215) who had at least one exacerbation, and
20 (9%) with two or more over the 12-month study period. Additional exacerbation data is
displayed in Table 2. Spearman’s rho identified a statistically significant (p=0.037) relationship
when testing for correlation between smoking status and number of COPD exacerbations. There
is a positive correlation of small effect size (r=0.142), indicating that current smokers have more
exacerbations than the former and never smokers. The only comorbidity that correlated with
COPD exacerbation was HF, which will be discussed further in the comorbidities subsection.
Primary Care Provider and Emergency Department Visits
Data regarding visits to the clinic PCP, Norton emergency department (ED), and Norton
hospitals is displayed in table 2. Most people (56%) had four or more PCP visits over the 12month period. Very few people had ED visits for COPD (<5%), however, the study was limited
to Norton ED visits only, and there are several other ED options within proximity to Norton ED
locations. About 27% of patients had ED visits for reasons other than COPD, however, the
specific reasons were not part of the study. No statistically significant relationships could be
found between number of PCP visits, ED visits or hospitalizations. Table 7 displays the
variables, p value, and the testing method compelling this conclusion.
Pharmacotherapy
Data was collected by type of medication and whether it was used for long-term disease
management, versus only used in times of exacerbation. The data collected on long-term
pharmacotherapy is reported in frequency and rate in table 2. Those with two or more (> 2)
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exacerbations per year are considered high-risk per GOLD (2015) measures, which places 20
(9%) patients from the study group (N=215) into patient Group C or D (see table 1 for grouping).
The recommended long-term medication options for Group C and D patients include: LAA only,
or ICS plus (+) LABA, or ICS + LABA + LAA. Figure 2 displays the medication combinations
used for the high-risk patients (n=20), and identifies an 85% compliance rate with recommended
long-term pharmacotherapy based on disease severity category.
Physician Quality Reporting System (PQRS) Performance Measure #52 is regarding
bronchodilator therapy for all patients with COPD (CMS, 2016). The 2014 benchmark for
bronchodilator therapy was reported at 92%. This performance measure for bronchodilator
therapy aligns with GOLD recommendations. This study found an 83% rate of long-term
bronchodilator therapy among the sample.
Standards of care for exacerbation treatment includes adding or increasing SABA and
SAA inhaled medications, and adding systemic antibiotic and/or systemic corticosteroid in some
cases, when appropriate. This study included antibiotic and corticosteroid administration as
variables for collection regarding exacerbation. Medication use across the entire sample
(N=215) is displayed in Table 2, and medications for exacerbation are in Table 8. There were 45
people (n=45) who had at least one exacerbation among the population (see data in table 2). Due
to data extraction difficulty, the addition of or increase in SABA and SAA medications as well as
indications for use of steroid and antibiotic medications were not study variables. Therefore, the
table 8 shows whether the patient with an exacerbation had SABA and/or SAA as long-term
medications, and whether systemic antibiotic and/or corticosteroid were additional exacerbation
treatments. All but two people (4%) in the group (n=45) were treated with one of the four
recommended medication combinations, thus, a 96% compliance rate with recommendations for
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exacerbation treatment was found. Most patients were treated with inhaled medication (SABA
and/or SAA) and both systemic antibiotic and systemic steroid therapy (56%).
Comorbid Conditions
There were nine comorbid conditions tracked, with a median number of two
comorbidities per patient (N=215). The comorbidities tracked in the study include: anxiety
and/or depression; atrial fibrillation (Afib); cognitive impairment; diabetes mellitus (DM);
gastroesophageal reflux disease (GERD); heart failure (HF); hypertension (HTN); lung cancer;
and, osteoporosis. Comorbidity frequencies and rates are displayed in table 2. The occurrence
rate of the top five occurring comorbidities is illustrated in figure 3, while figure 4 illustrates the
number of comorbidities present in each study subject.
Number of COPD exacerbations and presence of HF comorbidity were found to be
related. A Mann-Whiney U test revealed (U=2206.500, z=-3.412, p=0.001, r=-0.233) a
statistically significant difference of small effect size, in the number of exacerbations in those
who had HF (n=33). Therefore, those with HF (mean rank=132.14) were slightly more likely to
have had a COPD exacerbation than those studied (N=215) who did not have HF (mean
rank=103.62).
A Mann-Whitney U test revealed (U=1144, z=-3.142, p=0.002, r=-0.214) a statistically
significant difference of small effect size, in the number of comorbidities in those who had a
hospitalization for COPD (n=20, median=3 comorbidities) and those who did not have a
hospitalization for COPD (n=195, median=2 comorbidities). These findings indicate that the
more comorbidities a person has, the more likely they are to be hospitalized with a COPD
exacerbation.
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When examining each comorbidity in a Chi-square test for independence, HF and DM
were the comorbidities found to relate to hospitalization for COPD exacerbation. Those with
DM (n=68) were found to have a statistically significant (p=0.002) relationship of small to
medium effect size (r=0.230). Those with HF (n=20) were found to have a statistically
significant (p=0.000) relationship of medium effect size (r=0.308). Therefore, those with HF or
DM were more likely to have a hospitalization for COPD exacerbation than those without HF or
DM. No other comorbidities showed statistically significant relationships with hospitalizations,
however, some did not meet minimal sample size requirement for n.
Evidence points to association between anxiety and/or depression, and poor COPD
prognosis; with both anxiety and depression associating with younger age, female gender,
smoking, and lower FEV1 (GOLD, 2015). This study was not able to correlate the comorbidity
of anxiety and/or depression with female gender (p=0.271), smoking status (p=0.223),
hospitalizations for COPD (p=0.058), or other hospitalizations (p=0.394). Presence of anxiety
and/or depression was found to correlate with younger age (p=0.00), with the median age range
of 51-60 in patients with this comorbidity (n=97).
Summary of Hospital Admissions
Rather than evaluating hospitalizations only in terms of patients hospitalized (n=20), each
hospitalization (n=39) was also evaluated separately. As displayed in table 2, hospitalizations
were divided into two groups: hospitalization with COPD exacerbation; and, hospitalization for
anything other than COPD exacerbation. Both types of hospitalizations were subdivided into
four groups per number of hospitalizations: zero; one; two; three; and, four (the maximum
occurring number). For COPD exacerbation, there was a total of 39 hospital visits distributed
among 20 patients in the study group. Table 3 reports frequencies and rates of the six variables
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unique to hospitalizations with COPD exacerbation diagnoses (n=39): length of stay (LOS),
discharge disposition, follow-up PCP appointment in place at time of discharge (PCP
appointment at discharge), time from discharge to follow-up appointment (time to appointment),
time from discharge to follow-up visit (time to actual PCP visit), and readmitted within 30 days
of discharge for COPD (COPD readmission).
The median LOS was four days, with 87% of the group (n=39) having an LOS of seven
days or less. Discharge to home was the median and mode (69%) discharge disposition. Most
patients (67%) had an appointment with their PCP in place at time of discharge. However, there
is no indication in Epic when this appointment was made, thus, the appointment could have been
made without regard to hospitalization at the last PCP visit. This might explain why in 22 cases
(54%), the appointment was scheduled greater than 14 days following hospital discharge. In
44% of cases, patients had an actual PCP visit within 14 days; while 56% either had a visit
greater than 14 days from discharge, were readmitted to the hospital (28%) for COPD, or were
readmitted for something else (3%). Readmission for COPD exacerbation occurred 11 times
(28%) among seven patients. Among the patients hospitalized for COPD (n=20), seven (35%)
were readmitted at least one time for COPD. Readmission for reasons other than COPD
occurred one time (3%). It is unclear whether an intervention occurred to schedule PCP
appointments prior to hospital discharge. The variation in time from scheduled appointment and
actual visit might be explained by a care management or nurse navigator intervention (e.g. a
post-discharge phone call) to move the appointment time closer to the discharge date.
Among the hospitalizations (n=39), there were 11 readmissions (n=11) for COPD
distributed among seven total patients. Table 4 displays the basic demographic variables and
results for only the patients who had a COPD readmission (n=7). Additionally, the data specific
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to hospitalization for those patients is best viewed in a table comparing the initial hospitalization
with the subsequent readmissions, as in table 5. With such a small sample size of people who
were readmitted (n=7), it is difficult to determine relationships, therefore, the data is reported in
frequencies. Findings of interest include: in hospitalized patients (n=20) the median number of
exacerbations in hospitalized patients was two, whereas in readmitted patients (n=7) the median
was three; and, the median number of comorbidities in hospitalized patients was three, whereas
in readmitted patients the median was four. Another interesting finding was that there was little
difference between time to follow up visit between the two groups of hospitalizations. The
median time from discharge to PCP follow-up in all COPD hospitalizations (n=39) was >14
days, and for the readmissions (n=11), it was 11-14 days. Readmitted patients having a higher
number of comorbidities indicates they could be more ill and at higher risk for exacerbation than
those who were not readmitted. The minimal difference in time to follow-up indicates there
might have been an intervention, but there is room to improve in the higher risk patients.
Comparison of Data
One study concludes that highest risk patients should follow-up within seven days from
hospital discharge (Jackson et al., 2015); however, other study recommendations vary according
to risk and diagnosis. Timeliness is not specifically defined as a national best practice
recommendation, therefore, this study focused on 14 days or less for comparison with reported
data. Hospital compare (CMS, 2016) reports 2012 – 2015 readmission rates for both Norton
Healthcare and the nation of 20%. The hospitalizations in this study group (n=39) had a
readmission rate of 28%, indicating a performance worse than national and Norton averages.
Follow-up rates within 14 days of hospital discharge are compared in figure 5.
Comparisons are of the hospitalizations of this study group (n=39), with reported national and
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Norton Healthcare averages for HF (The Dartmouth Institute for Health Policy and Clinical
Practice [DAHC], 2016). No data could be found on COPD specifically for this measure, thus,
HF was used for comparison. Figure 5 shows that COPD patients of the study have lower rates
of PCP follow-up within 14 days of discharge than Norton Healthcare and the nation (for HF
hospital discharges), indicating performance below the national standard.
All identifiable significant relationships among variables were summarized in this results
section. There were 39 hospitalizations distributed among 20 patients, and there were 11
readmissions for COPD, distributed among seven patients. When testing for relationships
between COPD hospitalization variables and others, specific patients with a COPD
hospitalization were compared (n=20), thus making for a smaller sample for comparison.
Variables were often manipulated and recoded from ordinal variables into bivariate nominal
variables to enable various testing methods. The variables of interest in which there were no
identifiable relationships are reported in Table 9, along with p-values and testing methods.
Listed variables in table 9 are as follows: smoker (yes or no), smoking status (current, former, or
never), any hospitalization (ordinal range), any hospitalization status (yes or no), COPD
hospitalization (ordinal range), COPD hospitalization status (yes or no), readmission (yes or no),
number of comorbidities (ordinal range) number of PCP visits (ordinal range), ED for COPD
(ordinal range), ED for other than COPD (ordinal range), number of comorbidities (ordinal
range), PCP appointment at discharge (yes/no), follow-up visit within 14 days of discharge (yes
or no).
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Discussion
An exhaustive literature review of published studies has determined that this is the first
time an attempt has been made to establish a baseline of primary care management of COPD in
the U.S. per the updated GOLD (2015) guideline recommendations. This study was a
retrospective chart review conducted through the Epic EMR that included patients with COPD
(N=215) who had a visit within the 12 months of 2015 to the Norton Healthcare primary care
clinic studied. This study aimed to describe the characteristics of those studied, explore
relationships among key variables, and evaluate provider adherence to GOLD (2015) guideline
recommendations.
The first aim of this study was met by providing a description of the sample
demographics and health characteristics of the COPD patients in the Louisville, Kentucky
primary care clinic (N=215). The sample was majority white (65%), female (67%), current
smokers (52%), with a median age of 65. The payer distribution was divided among Medicare,
Medicaid, and commercial payers at a rate consistent with national rates. Resulting frequencies
and rates of data regarding demographic variables, exacerbations, outpatient and inpatient visits,
COPD pharmacotherapy, and comorbid conditions is displayed in table 2.
The significant relationships found were related to risk for exacerbation and
hospitalization. Statistically significant relationships regarding exacerbations included: current
smokers have more exacerbations than former and never smokers; those with HF tend to have
more COPD exacerbations than those without HF; those hospitalized with COPD exacerbation
tend to have more comorbidities than those who were not hospitalized; and, those with HF or
DM comorbidities are more likely to be hospitalized with COPD exacerbation. These findings
are not surprising, as it is widely accepted as fact that tobacco smoking is a risk factor for COPD
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and continued smoking in presence of COPD leads to more complicated and rapid disease
progression (GOLD, 2015). Studies have also established a connection between HF and COPD
exacerbations and hospitalizations, and indicate that it can be difficult to separate cause of
exacerbation with concomitance of HF and COPD due to both being diseases of exacerbation
and remission (Iversen et al., 2008).
With the connection between cardiovascular disease and lung disease, and DM and
cardiovascular disease (Mannino, Thorn, Swenson, & Holguin, 2008;) (GOLD, 2015), it is also
not surprising that a DM comorbidity is associated with higher risk of hospitalization for COPD
exacerbation. This study finding a relationship between a higher number of comorbidities and a
higher incidence of COPD hospitalization correlates with the previously established evidence
(GOLD, 2015).
Another aim of this study was to determine the degree to which the clinic adhered to
GOLD 2015 guidelines. Due to study design, the data collected, and the 2015 structure of the
Epic EMR, a complete assessment of guideline adherence could not be performed. Key GOLD
(2015) recommendations include: diagnostic spirometry evaluation; pharmacologic treatment
based on severity of disease (determined by spirometry results and symptoms); recommended
treatment of COPD exacerbations include adding/increasing inhaled SABA and/or SAA, and
adding systemic antibiotic and/or corticosteroid when appropriate; and, treating comorbidities
per the practice guidelines for those comorbidities. Without data collected on evaluation
procedures on all tracked comorbidities, it cannot be determined whether comorbidities were
treated in accordance with guideline recommendations.
Diagnostic spirometry data was a variable for collection until it was determined that
spirometry was not done or was not reliably reported in the EMR. The capability for spirometry
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use as an objective diagnostic tool was not present on site, and there was no standard location for
spirometry documentation in the EMR. The patient burden required an off-site visit at a
separately scheduled time. Burden on clinic providers/staff included ordering and submitting
referrals, obtaining records, and provider review/follow-up. These factors are highly likely to
have influenced spirometry evaluation for this population and can easily explain a lack of
spirometry for diagnosis. It is also likely that diagnosis of COPD was based on patient-reported
historical diagnosis and clinical presentation, rather than the diagnostic and staging criteria
defined by the GOLD 2015 guidelines.
The lack of variables to assess exacerbation further inhibited the ability to evaluate
whether recommendations for exacerbation pharmacotherapy were followed. However, GOLD
(2015) and CMS (2016) recommend long-term bronchodilator therapy at stages of disease, with
2014 national benchmark of 92% compliance. The study finding an 83% rate of compliance
with this recommendation indicates room for improvement. Another method used to determine
medication compliance was the pharmacologic treatment used in patients who had a COPD
exacerbation (n=45). The evaluation indicated that most patients (96%) were treated with GOLD
recommended therapies. The patients with two or more exacerbations (n=20) fit into the GOLD
high-risk grouping C or D; the evaluation of these therapies indicated an 85% compliance rate
with recommended long-term pharmacotherapy among these patients. Therefore, through the
information that is available, it can be stated that the clinic requires improvement in
bronchodilator therapy to meet the national benchmark. Without benchmark comparisons for the
others, it appears acceptable, the compliance rates of 96% and 85% for exacerbation and highrisk patient treatments respectively.
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Limitations
The study had a small sample size overall, in which the entire sample included 215 patients, with
39 total hospitalizations, and 11 readmissions. The small size limited the ability to test for
relationships among variables because the sample sizes were often too small for reliable testing
and/or had a low power of test results. The study design did not account for the overlap in
clinical presentation and treatment recommendations for COPD, asthma, and bronchitis, so
limiting data evaluation to only COPD exacerbation suggests disease process, specifically
exacerbations, were underreported in this study. The collection of data over one year, versus two
or more years of data limited the ability to grasp the big picture of disease progression and
disease management. Tracking exacerbation medications for this study included only the
addition of systemic corticosteroids and systemic antibiotics. Additional tracking of SABA and
SAA use for exacerbations was not done due to overlap with most patients being on long-term
SABA and/or SAA, and the inability to redesign methods for data collection. This limited the
ability to determine compliance with exacerbation treatment.
Possibly the largest limitation and factor inhibiting the ability to determine guideline
adherence, was the inability to stage the severity of COPD in the population. Without spirometry
data, it was impossible to measure guideline adherence due to guideline recommendations being
largely based on spirometry values. The study data only being from Norton facilities has an
unknown impact on the ability to fully appreciate the complete picture of the COPD disease
process and disease management. There are several non-Norton options for emergency and
hospital care in the Louisville area, and patients often require emergent care for COPD
exacerbations, and thus travel to the nearest medical facility. Finally, tracking only PCP visits

17

post-discharge versus including specialist visits such as pulmonology visits, might have led to
underreporting of timely hospital follow-up.
Practice Improvement Recommendations
The NHLBI (2012) reported rate of hospitalization is 15% for Kentucky residents over
age 55, and the admission rate for COPD of those in this study aged 55 and over was also 15%.
Considering the CMS (2016) PQI regarding hospital admissions for COPD and asthma, the 15%
admission rate and 28% readmission rate of those in this study (N=215), targeting a reduction in
hospitalizations is an appropriate goal for this clinic. A pilot program to better manage COPD in
the outpatient setting per GOLD guidelines with the goal of reduction in hospitalizations (and
readmissions) is the recommendation based on study findings and evidence-based practice
recommendations. Program aims include: 1) objective diagnosis and staging of COPD on all
patients; 2) optimize the EMR with COPD templates; and, 3) create a process for timely followup after hospitalization.
Additional study procedure recommendations include: account for specialist visits as data
variables, particularly pulmonology; include asthma exacerbation and acute bronchitis in
variables for collection; include all GOLD comorbidities and treatments as variables; collect data
on smoking cessation counseling and cessation treatments; and, include data regarding timely
follow-up intervention for those hospitalized with COPD exacerbations. Comparing the findings
of this study to those of future years could have broad implications for COPD management in
primary care.
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Timely Follow-up. Past study findings link timely outpatient follow-up after hospital
discharge with reduction in readmission rates (Jackson et al., 2015;) (Misky, Wald, & Coleman,
2010). Pittsburgh Regional Health Initiative (2011) recommends identifying patients at highest
risk for readmission and implementing a high-impact intervention that will improve transition
back to the community and prevent an avoidable hospital readmission. Jackson et al. (2015)
found that outpatient follow-up within 14 days of hospital discharge was associated with a 1.5%
to 19.1% reduction in readmissions, with the wide range due to varying risk groups. When
comparing the study population to Norton Healthcare and national averages, the study population
revealed a comparatively high readmission rate of 28% and a low rate of PCP follow-up within
14 days of 44%. Considering previous evidence suggesting the importance of timely follow-up,
as well as the relationship findings in this study between comorbidities and COPD
hospitalization, there is evidence that the clinic would benefit from a focus on timely PCP
follow-up after hospital discharge.
The goal includes improving the rate of follow-up within 14 days from 44% to at or
above 60%. The proposed intervention to achieve this goal includes the use of the outpatient
nurse navigator (already in place at the clinic) to ensure that a follow-up appointment is in place
prior to hospital discharge. Additionally, this nurse navigator will make a follow-up telephone
call within two days of hospital discharge to confirm the appointment and assist the patient with
any health questions or barriers to follow-up. Due to the study group having a higher-thanaverage COPD readmission rate, targeting timely follow-up could serve as a high-impact
intervention to reduce readmission rates. Specifically targeting those with HF and DM
comorbidities could also be impactful due to the relationship between those diagnoses and
hospital admission rates found in this study.
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Staging COPD Severity. Both GOLD (2015) and CMS (2016) agree that it is a
diagnostic necessity for patients with COPD to have at least baseline spirometry evaluation.
Spirometry is a low-cost, billable test that takes minimal time to perform, with results that can be
immediately interpreted by the PCP. The proposed intervention includes performing spirometry
in the clinic. This will require training medical assistants at test administration, obtaining the
required equipment, and dedicating a location in the clinic for performing spirometry. The
benefits to on-site spirometry evaluation include: a reduction in patient burden due to decreased
outpatient visits and cost; the results can be interpreted by the PCP immediately following
testing, therefore objectively guiding treatment per guidelines; and, the clinic will benefit from
an increased revenue.
Medical grade spirometry equipment can be purchased at a cost below $2,000, and
Medicare reimbursement for various spirometry tests ranges $36-$57 (Jones Medical Instrument
Company [Jones], 2015; QRS Diagnostics [QRS], 2012). If equipment is purchased for $2,000,
with four tests performed weekly, at an average reimbursement of $44 per test, the net revenue
after one year is $7,152. In this scenario, the return on investment is achieved in about 11 weeks.
Best practice recommendations, the results of this study, and spirometry revenues lead to a
strong recommendation that this primary care clinic have spirometry evaluation capability,
trained spirometry administrators, and the goal of baseline spirometry evaluation in all patients
with COPD. Spirometry and Epic optimization to prompt providers to obtain spirometry
evaluation is a recommendation based on the existing evidence and findings in this study.

20

Optimization of the Electronic Medical Record. Optimization of the EMR is an
ongoing process at Norton Healthcare, and has not occurred system-wide to specifically target
COPD management in primary care. Results from this study indicate need for improvement in
GOLD (2015) guideline adherence, and the use of EMR templates for chronic disease
management has been shown to align patient care with EBP guidelines (Gronkiewicz, BorkgrenOkonek, Diamond, & Hickam, 2009). The recommended intervention is to implement an
evidence-based template in the EMR for COPD management in primary care.
Recent Epic optimization has occurred to improve DM management per guideline
recommendations. This includes a template of best practice recommendations and a standard
location in which to document DM care. It is recommended that the COPD template includes
disease symptoms, spirometry values (and corresponding date), COPD staging, pharmacologic
treatment regimen, GOLD comorbidities, and dates of recent exacerbations and treatments. The
template should also include provider prompts to guide care per recommendations. The use of
COPD templates has the potential to improve patient health outcomes, as well as improved
reported measures such as bronchodilator therapy and spirometry. An additional benefit of
optimizing the EMR to include these components, is that it will simplify future studies
measuring guideline adherence, and change in patient outcomes such as hospitalizations and
exacerbations.
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Conclusion
The data and analysis regarding hospitalizations and comorbidities have provided
valuable results with implications for practice improvement and future research. Results from
this study indicate that the implementation of evidence-based practice change initiatives will
improve the health outcomes of patients with COPD. Implementing the suggested program
interventions incorporates every aspect of the Triple Aim (IHI, 2016). The process for timely
follow-up puts patients at the center of care includes their best interest as well as cost-reduction
in the efforts to promote health and reduce hospital readmissions. The spirometry intervention
will reduce the patient burden of an off-site visit, it will objectively guide treatment to improve
health outcomes, and will help achieve reduced costs by improving health and reducing both
outpatient and hospital visits. Optimization of the EMR with COPD templates will enable
patients to better report their symptoms, providers to better treat their disease, and improved
outpatient disease management will be cost-effective in that it will reduce hospitalizations.
Professional next steps as a Doctor of Nursing Practice will be to share these study
findings with stakeholders and obtain buy-in for the pilot program. It will be necessary to
explore potential barriers and modify the program to optimize potential outcomes, as well as
develop an implementation and evaluation method for the proposed program. Adapting the 2015
study per previously mentioned criteria will enable 2016 data collection for additional baseline
data prior to program implementation. Following at least one year of program implementation, a
pre-post retrospective study could provide broad implications to inform quality improvement
initiatives for the management of COPD in the primary care setting.
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Table 1
GOLD (2015) Pharmacotherapy Management Recommendations for Stable COPD
Patient Group

First Line Therapy
A

SAA PRN
or
SABA PRN

B

LAA
or
LABA

C

ICS + LABA
or
LAA

D

ICS + LABA
and/or
LAA

Note. Adapted from GOLD (2015) recommendations.
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Table 2
Variables, Measures, and Results for Basic Demographic Data (N=215)
Frequency

Ratea

40-50

19

9

51-60

60

28

61-70

62

29

71-80

45

21

81 and over

29

14

141

66

72

34

2

1

145

67

Male

70

33

Other

0

0

Medicare

139

65

Medicaid

52

24

Commercial/Private

22

10

2

1

111

52

Former (quit prior to 2015)

93

43

Never Smoker

11

5

Zero

170

79

One

25

12

Two

11

5

Three

3

1

Four or more

6

3

Variable
Age

Race/ethnicity
Caucasian/White
African American/Black
Other or Unknown
Gender
Female

Insurance Provider

Other or none
Smoking Status
Current (ever smoked in 2015)

Number of exacerbations

28

Number of PCP visits
One

18

8

Two

41

19

Three

35

16

121

56

Zero

205

95

One

7

3

Two

3

1

Zero

157

73

One

38

18

Two or more

47

9

SABA

179

83

LABA

133

62

SAA

36

17

LAA

70

33

ICS

134

62

17

8

25

12

Steroid Only

6

3

Antibiotic Only

5

2

Neither

9

4

170

79

160

74

Anxiety and/or Depression

97

45

GERD

71

33

Diabetes

68

32

HF

33

15

Afib

22

10

Osteoporosis

15

7

Cognitive Impairment

11

5

5

2

Four or more
ED for COPD

ED for Other

Long-Term Pharmacotherapy

None
Exacerbation Pharmacotherapy
Both

N/A (no exacerbation)
Comorbid conditions
HTN

Lung Cancer

29

Number of hospitalizations – Non-COPD
exacerbation diagnosis (all other hospitalizations)
Zero

166

77

One

30

14

Two

10

5

Three

3

1

Four or more

6

3

Zero

195

91

One

9

4

Two

4

2

Three

6

3

Four or more

1

1

Number of hospitalizations - COPD exacerbation

Note. aRate as percent (%) rounded to nearest whole number.
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Table 3
Variables, Measures, and Results for COPD Hospitalizations (n=39)
Frequencya

Rateb

Equal to 1 day

3

8

2-3 days

7

18

4 days

12

31

5-7 days

12

31

8-10 days

1

3

11-14 days

2

5

More than 14 days

2

5

27

69

Home with home health

4

10

Subacute rehabilitation

1

3

Skilled nursing facility

1

3

Pulmonary rehabilitation (outpatient)

5

13

Death prior to discharge

1

3

Yes

26

67

No

12

31

N/A

1

3

4 days or less

3

8

5-7 days

1

3

8-10 days

0

0

11-14 days

0

0

More than 14 days

22

54

N/A

13

36

Variable
Length of stay

Discharge disposition
Home

PCP appointment at discharge

Time to appointment

31

Time to actual PCP visit
4 days or less

7

18

5-7 days

5

13

8-10 days

2

5

11-14 days

3

8

More than 14 days

10

26

N/A

12

31

Yes

11

28

No

27

69

1

3

COPD Readmission

N/A (readmission for non-COPD reason)

Note. an = 39 in each variable category. bRate (%) rounded to nearest whole number and totals per category are
approximately 100%
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Table 4
Variables, Measures and Results for Patients with COPD Readmissions (n=7)
Variable

Frequency

Age
40-50

1

51-60

2

61-70

2

71-80

2

81 and over

0

Race/ethnicity
Caucasian/White

2

African American/Black

5

Other or Unknown

0

Female

5

Male

2

Other

0

Gender

Insurance Provider
Medicare

6

Medicaid

1

Commercial/Private

0

Other or none

0

Smoking Status
Current (ever smoked in 2015)

5

Former (quit prior to 2015)

2

Never Smoker

0

Number of exacerbations
Zero

0

One

1

Two

1

Three

2

Four or more

3

33

Number of PCP visits
One

0

Two

0

Three

0

Four or more

7

ED for COPD
Zero

5

One

0

Two

2

ED for Other
Zero

3

One

2

Two or more

2

Long-Term Pharmacotherapy
SABA

7

LABA

6

SAA

4

LAA

4

ICS

5

None

0

Exacerbation Pharmacotherapy
None

0

SABA and/or SAA only

0

SABA and/or SAA

0

and Antibiotic
SABA and/or SAA

1

and Steroid
SABA and/or SAA

6

and Steroid
and Antibiotic

34

Comorbid conditions
HTN

7

Anxiety and/or Depression

1

GERD

3

Diabetes

4

HF

3

Afib

1

Osteoporosis

1

Cognitive Impairment

1

Lung Cancer

1

Number of hospitalizations – Non-COPD
exacerbation diagnosis (all other hospitalizations)
Zero

4

One

2

Two

0

Three

0

Four or more

1

Number of hospitalizations – COPD exacerbation
Zero

0

One

0

Two

2

Three

4

Four or more

1
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Table 5
Comparison of Variables, Measures and Results for Patients with COPD Readmissions (n=7)
Admissiona

Readmissionb

Readmissionc

Readmissionc

Equal to 1 day

0

0

1

0

2-3 days

1

1

0

0

4 days

0

3

2

0

5-7 days

4

1

2

0

8-10 days

1

0

0

0

11-14 days

0

2

0

0

More than 14 days

1

0

0

1

Home

3

4

2

1

Home with home health

2

1

1

0

Subacute rehabilitation

1

0

0

0

Skilled nursing facility

0

0

1

0

Pulmonary rehabilitation (outpatient)

0

2

1

0

N/A (death)

1

0

0

0

Yes

4

5

3

0

No

3

2

2

1

4 days or less

1

0

1

0

5-7 days

0

0

0

0

8-10 days

0

0

0

0

11-14 days

0

0

0

0

More than 14 days

3

5

2

0

N/A (no appointment, death, or

3

2

2

1

Variable
Length of stay

Discharge disposition

PCP appointment at discharge

Time to appointment

readmission)

36

Time to actual PCP visit
4 days or less

0

2

2

0

5-7 days

2

1

0

1

8-10 days

1

0

0

0

11-14 days

0

0

1

0

More than 14 days

0

1

2

0

N/A (no appointment, death, or

4

3

0

0

Yes

6

4

1

0

No

1

3

4

1

Yes

4

2

0

0

No

3

5

5

1

readmission)
COPD Readmission

Readmission prior to follow-up visit

Note. aColumn total for each section = 7. bColumn total for each section = 7. cColumn total for each section = 5.
d
Column total for each section = 1
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Table 6
Relationships Among Insurer and COPD Hospitalization (N=215)
Variables

p-Value

Test

Medicare and COPD hospitalization

p=0.301

Mann-Whitney U

Medicare and COPD readmission

p=0.787

Chi-square

Medicaid and COPD hospitalization

p=0.651

Mann-Whitney U

Medicaid and COPD readmission

p=1.0a

Chi-square

Note. aMinimum cell count for testing not met.
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Table 7
Relationships Among Number of PCP Visits and ED or Hospital Visits (N=215)
Variables

p-Value

Test

PCP and ED COPD

p=0.477

Spearman’s rho

PCP and ED for reason other than COPD

p=0.203

Spearman’s rho

PCP and ED for any reason

p=0.492

Mann-Whitney U

PCP and Hospitalizations for COPD

p=0.131

Spearman’s rho

PCP and Hospitalization for any reason

p=0.155

Mann-Whitney U
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Table 8
Medications Used in Patients with COPD Exacerbation (n=45)
Medication Type

Frequency

Rate (%)

None

2

4

SABA and/or SAA only

7

16

SABA and/or SAA
and Antibiotic

5

11

SABA and/or SAA
and Steroid

6

13

SABA and/or SAA
and Steroid
and Antibiotic

25

56

Total

45

100

40

Table 9
Variables of Interest Without Established Significant Relationships (N=215)
Variables

p-Value

Test

Smoker and COPD hospitalization

p=0.197

Mann Whitney U

Smoker and readmission

p=1.0a

Chi-square

Smoking status and COPD hospitalization

p=0.154

Spearman’s rho

Smoking status and any hospitalization

p=0.857

Spearman’s rho

Number PCP and any hospitalization status

p=0.155

Mann Whitney U

Number PCP and COPD hospitalization

p=0.131

Spearman’s rho

Number PCP and ED for COPD

p=0.477

Spearman’s rho

Number PCP and ED for other

p=0.203

Spearman’s rho

Number of comorbidities and readmission

p=0.4

Mann Whitney U

PCP appointment at discharge and readmission

p=0.396

Chi-square

Follow-up visit and readmission

p=0.74

Chi-square
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Figure 1. Comparison of COPD Healthcare Cost Payers
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Figure 2. Pharmacotherapy Combinations for High-Risk Patients (n=20)
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Figure 3. Occurrence Rate (%) of Top 5 Comorbidities (N=215)
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